Sigrid Skånland
@sigridskanland.bsky.social
Project group leader and researcher at Institute for Cancer Research, Oslo University Hospital. Developing functional precision medicine for hematologic malignancies.
Sometimes photographer.
https://www.ous-research.no/skanland
Sometimes photographer.
https://www.ous-research.no/skanland
🎉Hurrah! Our paper is online!
In our most recent study we show that protein profiling of tumor cells can predict how patients with #CLL will respond to treatment with the PI3K inhibitor #umbralisib, either as a alone or with the BTK inhibitor #acalabrutinib.
aacrjournals.org/clincancerre...
In our most recent study we show that protein profiling of tumor cells can predict how patients with #CLL will respond to treatment with the PI3K inhibitor #umbralisib, either as a alone or with the BTK inhibitor #acalabrutinib.
aacrjournals.org/clincancerre...
Protein profiles predict treatment responses to the PI3K inhibitor umbralisib in patients with chronic lymphocytic leukemia
Abstract. Purpose: The management of chronic lymphocytic leukemia (CLL) has significantly improved with targeted therapies. However, many patients experience a suboptimal response. To optimally select...
aacrjournals.org
March 22, 2025 at 2:29 PM
🎉Hurrah! Our paper is online!
In our most recent study we show that protein profiling of tumor cells can predict how patients with #CLL will respond to treatment with the PI3K inhibitor #umbralisib, either as a alone or with the BTK inhibitor #acalabrutinib.
aacrjournals.org/clincancerre...
In our most recent study we show that protein profiling of tumor cells can predict how patients with #CLL will respond to treatment with the PI3K inhibitor #umbralisib, either as a alone or with the BTK inhibitor #acalabrutinib.
aacrjournals.org/clincancerre...
A presentation I gave at the
#EHA congress in 2022 resulted in this nice collaboration with #MartinaSeiffert that confirms findings from our group that #ProteasomeInhibitors may have therapeutic efficacy in relapsed #CLL.
Very nice to see this out!👇
www.nature.com/articles/s41...
#EHA congress in 2022 resulted in this nice collaboration with #MartinaSeiffert that confirms findings from our group that #ProteasomeInhibitors may have therapeutic efficacy in relapsed #CLL.
Very nice to see this out!👇
www.nature.com/articles/s41...
Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL - Nature Communications
The molecular mechanisms underlying resistance to therapy in Chronic lymphocytic leukemia (CLL) remain to be explored. Here, the authors perform multi-omics analysis in a mouse model of ibrutinib resi...
www.nature.com
January 29, 2025 at 11:19 AM
A presentation I gave at the
#EHA congress in 2022 resulted in this nice collaboration with #MartinaSeiffert that confirms findings from our group that #ProteasomeInhibitors may have therapeutic efficacy in relapsed #CLL.
Very nice to see this out!👇
www.nature.com/articles/s41...
#EHA congress in 2022 resulted in this nice collaboration with #MartinaSeiffert that confirms findings from our group that #ProteasomeInhibitors may have therapeutic efficacy in relapsed #CLL.
Very nice to see this out!👇
www.nature.com/articles/s41...